A major reshuffling at the FDA opened the road for Biogen’s Alzheimer’s drug. Can it cross the finish line?
All things considered, Biogen has walked a relatively easy road to next Monday’s approval decision for its controversial Alzheimer’s drug aducanumab.
After flunking a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
